A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment

CompletedOBSERVATIONAL
Enrollment

1,617

Participants

Timeline

Start Date

December 29, 2019

Primary Completion Date

October 31, 2020

Study Completion Date

October 31, 2020

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

Tiotropium + Olodaterol

Spiolto®

DRUG

Other LABA/LAMA

tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium

DRUG

LAMA

aclidinium bromide, glycopyrronium, tiotropium, umeclidinium

Trial Locations (12)

100

National Taiwan University hospital, Taipei

104

Makay memorial hospital, Taipei

112

Cheng Hsin general hospital, Taipei

220

Far east memorial hospital, New Taipei City

231

Taipei Tzu Chi hospital, Taipei

333

CGMH Linkou, Taoyuan

404

China medicine memorial hospital, Taichung

407

VGH Taichung, Taichung

600

Ditmanson Medical Foundation Chia - Yi Christian Hospital, Chia YI City

613

CGMH Chia YI, Chia YI City

824

Eda hospital, Kaohsiung City

833

CGMH Kaohsiung, Kaohsiung City

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY